1775-P: Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis

Introduction and Objective: In SUSTAIN 6 (NCT01720446), once-weekly subcutaneous semaglutide (0.5/1.0 mg) significantly reduced the risk of major adverse cardiovascular (CV) events (MACE) in people with type 2 diabetes (T2D) and established CV disease/high CV risk. This post hoc analysis assessed cardiorenal benefits of semaglutide across T2D phenotypic subtypes. Methods: The Discriminative Dimensionality Reduction Tree algorithm mapped 3251 SUSTAIN 6 participants to a non-linear 2-dimensional tree structure using 9 age- and sex-adjusted phenotypes. Correlations between phenotypes and cardiorenal outcomes from baseline to week 104 were visualized, and Cox proportional hazard models were used to determine semaglutide treatment efficacy on cardiorenal outcomes. Results: Four quadrants reflecting T2D subtypes were defined based on phenotype distribution (Figure A). Probability of 3-point MACE was lower with semaglutide vs placebo across subtypes (Figure B). Semaglutide reduced the risk of 3-point MACE, expanded composite CV outcomes, an additional composite outcome, and new or worsening nephropathy, across different T2D subtypes (Figure C). Conclusion: Semaglutide reduced the risk of cardiorenal outcomes across different T2D subtypes. Disclosure W. Wang: None. J. Zhang: None. B. Dong: Employee; Current; Novo Nordisk. P. Hu: Employee; Current; Novo Nordisk A/S. N. Marx: Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Abbott. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Abbott. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Amgen Inc. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; AstraZeneca. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; AstraZeneca. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Bayer AG. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Bayer AG. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Boehringer Ingelheim International GmbH. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Boehringer Ingelheim International GmbH. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Daiichi Sankyo. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; F. Hoffmann-La Roche Ltd. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Lilly. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Lilly. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Novo Nordisk. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Novo Nordisk. Other - Speaker - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Sanofi. Other - Consultant - Nikolaus Marx declines all personal compensation from pharma or device companies. All contracted fees and travel support are paid to the University Hospital RWTH Aachen. All contracts are between the University Hospital RWTH Aachen and the company.; Current; Sanofi. S.P. Prabhu: Employee; Current; Novo Nordisk A/S. Z. Shen: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. Q. Pan: None. L. Guo: Consultant; Current; Abbott Diabetes, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Dreisamtech, Dongbao, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Hansoh, Hengrui, Hua Medicine, Huadong Medicine, Innovent, Johnson & Johnson, Novartis AG, Novo Nordisk, Merck & Co., Inc., Pfizer Inc., Sanofi, Synapsor, Takeda Pharmaceutical Company Limited, Zense, 3sbio. Research Support; Current; Abbott Diabetes, AstraZeneca, Bayer AG, Dreisamtech, Eli Lilly and Company, Hansoh, Hengrui, Hua Medicine, Huadong Medicine, Innovent, Meitekanger, Novo Nordisk, Salubris, Sanofi, Synapsor, Zense.